Notecards - The ASCO Post

Testosterone Recovery After Androgen-Deprivation Therapy Linked to Improved Survival in High-Risk Prostate Cancer

Testosterone recovery to normal levels after long-term term androgen-deprivation therapy and radiotherapy significantly improved overall survival in patients with high-risk prostate cancer, according to data presented at the 2025 ASCO Genitourinary Cancers Symposium.

Chase Doyle

The ASCO Post 2/27/2025 12:04 PM

1. Testosterone recovery after long-term androgen-deprivation therapy and radiotherapy improves overall survival in high-risk prostate cancer. 2. PCS4 trial: 46% reduction in mortality risk among patients with recovered testosterone levels. 3. Duration of androgen-deprivation therapy did not directly impact overall survival. 4. 57% of patients receiving 18 months had testosterone recovery compared to 44% with 36 months. 5. The study advocates for a more nuanced approach to androgen-deprivation therapy duration and endocrine recovery in prostate cancer management.